Royalty Pharma raises 2026 guidance after 14% Royalty Receipts growth in Q2
The company cited new drug approvals and an expanded pipeline as it lifted its full-year Portfolio Receipts outlook to $3,400 million to $3,500 million.
SEC filing
Latest
1 story